$150-300k
+ Variable compensation in the form of sign-on and year-end bonuses
More information about location
3-5 days a week in office
Computational drug discovery and machine learning
Posted today
Computational drug discovery and machine learning
101-200 employees
Posted today
$150-300k
+ Variable compensation in the form of sign-on and year-end bonuses
More information about location
3-5 days a week in office
101-200 employees
To understand the behaviour of biologically and pharmaceutically significant molecules at an atomic level of detail, and to design precisely targeted, highly selective drugs for the treatment of various diseases.
Jump to section
To understand the behaviour of biologically and pharmaceutically significant molecules at an atomic level of detail, and to design precisely targeted, highly selective drugs for the treatment of various diseases.
Founded by American scientist David E Shaw, DE Shaw Research studies pharmaceutically and biologically significant molecules on an atomic level, with the intention of developing drugs that aid the treatment of diseases.
To aid in this, it designed a supercomputer that accelerates the process of molecular dynamics simulation. Unlike earlier special-purpose systems for molecule simulations, it runs its analysis on a specialised application-specific integrated circuit (ASIC), rather than dividing the computational power across different systems. This supercomputer has greatly accelerated molecular research for pharmaceuticals, and it's supported by the National Institutes of Health in the USA.
With tremendous national academic and healthcare backing behind it, DE Shaw Research holds an important space within the pharmaceutical research industry, and will no doubt continue to lead the way as its supercomputing technology evolves.
Kirsty
Company Specialist at Welcome to the Jungle
David E Shaw
(Founder & Chief Scientist)Previously a Senior Research Fellow at Columbia University and was the CEO of the Stanford Systems Corporation.